EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte Studie

Comparison of the efficacy of pioglitazone and metformin on ultrasound grade and liver enzymes level in patients with non-alcoholic fatty liver disease: A randomized controlled clinical trial

Manouchehr Khoshbaten, Samineh Beheshtirouy, Shahrzad Shayanrad, Afshin Gharekhani, Haleh Rezaee

Drug Research · 01.04.2023 · 73 (04) · 232-237

DOI: 10.1055/a-1997-0401 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Drug Research, erschienen am 01.04.2023. Verfasst von Manouchehr Khoshbaten und 4 weiteren Autor:innen. Beteiligte Einrichtung: Liver and Gastrointestinal Diseases Research Center, Tabriz University of Medical Sciences, Tabriz, Iran. Hauptthemen laut MEDLINE: Metformin, Non-alcoholic Fatty Liver Disease. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 20 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

This study aimed to evaluate the effectiveness of metformin and pioglitazone in combination with vitamin E on sonography grade and liver enzymes level in patients with non-alcoholic fatty liver disease.

Methods

A randomized controlled clinical trial was designed with 68 patients diagnosed with non-alcoholic fatty liver disease by sonography and clinical examinations. Sixty-eight patients were randomly divided into two groups; 34 were assigned to receive 15 mg of pioglitazone per day and 34 were assigned to receive 1000 mg of metformin per day for 6 months. All of the patients received vitamin E at a dose of 800 IU daily for six months. The sonography grade of fatty liver and the levels of alanine aminotransferase and aspartate aminotransferase of patients were evaluated at baseline, and within three and six months after initiation of the intervention.

Results

The use of metformin or pioglitazone in combination with vitamin E decreased the sonography grade of non-alcoholic fatty liver disease patients after 6 months of treatment (p-value

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MetforminNon-alcoholic Fatty Liver DiseaseHumansPioglitazoneHypoglycemic AgentsAlanine TransaminaseVitamin EAspartate Aminotransferases

Substanzen

MetforminPioglitazoneHypoglycemic AgentsAlanine TransaminaseVitamin EAspartate Aminotransferases

Autor:innen und Institutionen

  • Liver and Gastrointestinal Diseases Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
  • Department of clinical pharmacy, Faculty of pharmacy, Tabriz University of Medical, Sciences, Tabriz, Iran.
  • Student Research Committee, Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran.

Zitieren

APA

Khoshbaten, M., Beheshtirouy, S., Shayanrad, S., Gharekhani, A., & Rezaee, H. (2023). Comparison of the efficacy of pioglitazone and metformin on ultrasound grade and liver enzymes level in patients with non-alcoholic fatty liver disease: A randomized controlled clinical trial. Drug Research, 73(04), 232-237. https://doi.org/10.1055/a-1997-0401

Vancouver

Khoshbaten M, Beheshtirouy S, Shayanrad S, Gharekhani A, Rezaee H. Comparison of the efficacy of pioglitazone and metformin on ultrasound grade and liver enzymes level in patients with non-alcoholic fatty liver disease: A randomized controlled clinical trial. Drug Research. 2023;73(04):232-237. doi:10.1055/a-1997-0401

BibTeX
@article{Khoshbaten2023,
  author = {Khoshbaten, Manouchehr and Beheshtirouy, Samineh and Shayanrad, Shahrzad and Gharekhani, Afshin and Rezaee, Haleh},
  title = {Comparison of the efficacy of pioglitazone and metformin on ultrasound grade and liver enzymes level in patients with non-alcoholic fatty liver disease: A randomized controlled clinical trial},
  journal = {Drug Research},
  year = {2023},
  volume = {73},
  number = {04},
  pages = {232--237},
  doi = {10.1055/a-1997-0401}
}
Kostenlos starten →